about
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeThe Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - RoscovitineTherapeutic drug monitoring of antimicrobials.Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignanciesMonitoring drug therapy.Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.My child is unique; the pharmacokinetics are universal.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients.Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients.A Bayesian dose-individualization method for warfarin.Development of a bayesian forecasting method for warfarin dose individualization.A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.Developmental pharmacology; filling one knowledge gap in pediatric anesthesiology.A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
P2860
Q34571082-E11636AC-B940-4E7E-A8B4-46208D5FEEA6Q35062145-00C75FF6-A595-4698-ABAD-0EF041CA7F1FQ35640430-F9B1332F-A0A1-4D1E-A603-00AA4261B45DQ35748477-1F318158-AA75-4E60-903F-ACAD308E1537Q36081472-638734F8-410B-4AA6-944E-F57F155B399EQ36094786-B04B8F62-5FEB-4D9B-8AC2-32AD29B907EDQ37973872-026C1533-55C9-487E-BCC1-1A602F618639Q38004063-B1A7AF62-FBE5-47A3-AB35-439B548EAA48Q38137251-888988B2-BA8A-48BB-99EC-636694098E20Q38610672-6F864B11-C57E-45ED-86CB-4722EED94B69Q39483373-AC4C78F8-D5F5-4FC4-99B0-5569AFB0E992Q39785314-F7092E3F-DB08-4316-9DC8-1998F7345A42Q40554814-14D6C3D6-805C-4587-85EA-C5AFA60B0F42Q43188221-5D59BC50-9540-42B9-8832-50E2FE4DF09FQ46367785-C4E8894E-E936-402E-8B75-DE6A0C2CBCA0Q48286613-B9EB969F-6605-4E3A-B608-D7077B7641D8Q51118472-C93D2F87-E877-4B72-8D8A-21A8E7B5D048
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Target concentration intervention: beyond Y2K.
@ast
Target concentration intervention: beyond Y2K.
@en
Target concentration intervention: beyond Y2K.
@nl
type
label
Target concentration intervention: beyond Y2K.
@ast
Target concentration intervention: beyond Y2K.
@en
Target concentration intervention: beyond Y2K.
@nl
prefLabel
Target concentration intervention: beyond Y2K.
@ast
Target concentration intervention: beyond Y2K.
@en
Target concentration intervention: beyond Y2K.
@nl
P1476
Target concentration intervention: beyond Y2K.
@en
P2093
Holford NH
P304
P356
10.1046/J.1365-2125.2001.00971.X
P407
P478
52 Suppl 1
P577
2001-01-01T00:00:00Z